Serotonin syndrome associated to the use of paroxetine: Case report;Sindrome serotoninergica associada ao uso de paroxetina: Relato de caso

Arquivos de Neuro-Psiquiatria

Volumn 57, Issue 3 B, 1999, Pages 886-889

  Cavallazzi, Luís Otávio ^a   Grezesiuk, Anderson K ^a  

^a NONE

Author keywords

Myoclonus; Paroxetine; Serotonin syndrome

Indexed keywords

CLONAZEPAM; DIAZEPAM; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; ELECTROENCEPHALOGRAM; FEMALE; HEADACHE; HUMAN; MYOCLONUS; SEROTONIN SYNDROME; CHEMICALLY INDUCED DISORDER;

ADULT; FEMALE; HUMANS; MYOCLONUS; PAROXETINE; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 0033186480     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X1999000500027     Document Type: Article

References (34)

1. Richard IH, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-1077.
2. Egberts ACG, Borgh J, Brodie-Mejer CCE. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Internat Clin Psychopharmacol 1997;37:519-521.
3. Dursun SM, Mathew VM, Reveley MA, Sternbach R. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993;342:442-443.
4. Lejoyeux M, Rouillon F, Ades J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand 1993 Nov:88(5):369-371.
5. Totten VY, Hirschenstein E, Hew P. Neuroloptic malignant syndrome presenting without initial fever:a case report. J Emerg Med 1994;12:43-47.
6. Bodner RA, Lyncb L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-223.
7. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-533.
8. Mathew NT, Tiejen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996;16:323-327.
9. Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdmoglu AK Serotonin syndrome induced by transiotioning from phenelzine to venlaxine: four patients reports. Neurology 1998;51:275-276.
10. Kudo K, Sasaki I, Tsichiyama K, Akiyoshi J, Nagayama H, Fujii I. Serotonin syndrome during clomipramine monotherapy:comparison of two diagnostic criteria. Psychiatry Clin Neurose 1997;13:4306-4307.
11. Ebert D, Albert R, May A, et al. The serotonin syndrome and psychosis-like side-effects of fluvoxamine clinical usean estimation of incidence. Eur Neuropsychopharmacology 1997;30:71-74.
12. Bertorini TE. Myoglobinyria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol Clin 1997;53:649-671.
13. Dike GL. Trifasic waves in serotonin syndrome. J Neurol Neurosurg Psychiatry 1997;62:200-201.
14. Wiklund L, Sjolund B, Bjorklund A. Morphological and functional studies on the serotoninergic inervation of the inferior olive. J Physiol(Paris)1981;77:183-186.
15. Burns TG, Szechtman H, Brown GM, Snieckus V. Behavioral effects of 5-hydroxy-N-acetyltryptophan, a putative synthetic precursor of N-acetylserotonin. Progr Neuropsychopharmacol Biol Psychiatry 1983;6:359-363.
16. Robertson B, Baker GB, Vanderwolf CH. The effects of serotonergic stimulation on hippocampal and neocortical slow and behavior. Brain Res; 55:265-275.
17. Nimmo SM, Kennedy BW, Tullett WM, Blyth AS, Dougall JR. Drug-induced hyperthermia Anaesthesia 1993;48:892-895.
18. Green AR, Cross AJ, Goodwill GM. Review of pharmachology and clinical pharmacology of 3, 4-methylene-dioxymethamphetamine(MDMA or "ecstasy"). Psychopharmacology(Berl) 1995;119:247-260.
19. Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from velaxine-tranylcylpromine interaction Vet Hum Toxicol 1996;38:358-361.
20. Misane I, Johansson C, Ogren SO. Analysis of the 5-HTIA receptor involvement in passive avoidance in the rat. Br J Pharmacol 1998;25:499-509.
21. Martin TG. Serotonin syndrome Ann Emerg Med 1996;28:520-526.
22. Mitchell PB, Drug interactions of clinical significance with selective serotonin reuptake inhibitors Drug Saf 1997;17:390-406.
23. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994:24;983-985.
24. Weiner AL, Tilden FF Jr. McKay CA Jr. Serotonin syndrome:case report and review of the literature. Conn Med 1997;61:717-721.
25. Lucki I, Frazer A. Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants. Psychopharmacocology (Berl)1982;77:205-211.
26. Guze BH, Baxter LR Jr. The serotonin syndrome:case responsive to propanolol J Clin Psychopharmacol 1986;6:119-120.
27. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994;335:1021-1022.
28. Gillman PK. Successful treatment of serotonin syndrome with chlorpromazine Med Aust 1996;165:345-346.
29. Hoes MJ, Zeijpveld JH. Mirtazapine as treatment for serotonin syndrome. Biol Psychiatry 1996;39:384-385.
30. Brown TM, Skop BP. Nitroglycerin in the treatment of the serotonin syndrome. Ann Pharmacother 1996;30:191-192.
31. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-533.
32. François B, Marquet P, Desachy A, Roustan J, Lachatre G, Gastine H. Serotonin syndrome due to an overdose of moclobemide and clomipramine: a potentially life-threatening association. Intens Care Med 1997;23:122-124.
33. Szuba MP, Horning M, Amsterdam JD. Rapid conversion from one monoamine oxidase inhibitor to another. J Clin Psychiatry 1997;58:307-310.
34. Scweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998;19:455-464.